Patents by Inventor Matthias Eberhard Glaser
Matthias Eberhard Glaser has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 10220105Abstract: The present invention relates to the field of radiopharmaceuticals for in vivo imaging, in particular to automated methods for the preparation and purification of 18F-labelled tau imaging radiotracers. Also provided are interchangeable cassettes useful in the methods, and the use of automated synthesizers and cassettes in the methods.Type: GrantFiled: December 16, 2014Date of Patent: March 5, 2019Assignee: GE HEALTHCARE LIMITEDInventors: Duncan George Wynn, Steven Michael Fairway, Matthias Eberhard Glaser, Ian Newington, Gareth Edwin Smith, Imtiaz Ahmed Khan, Julian Grigg
-
Patent number: 10201625Abstract: Novel radiotracer(s) for Positron Emission Tomography (PET) imaging are described. Novel radiotracer(s) for Positron Emission Tomography (PET) imaging of neuorendocrine tumors are described. Specifically the present invention describes novel [18F]Fluoroethyltriazol-[Tyr3]Octreotate analogs; in particular those that target somatostatin receptors found on the cell surface of gastroenteropancreatic neuorendocrine tumors. The present invention also describes intermediate(s), precursor(s), pharmaceutical composition(s), methods of making, and methods of use of the novel radiotracer(s).Type: GrantFiled: March 1, 2012Date of Patent: February 12, 2019Assignees: IMPERIAL COLLEGE, GE HEALTHCARE LIMITEDInventors: Sajinker Kaur Luthra, Julius Leyton, Eric Ofori Aboagye, Lisa Iddon, Bard Indrevoll, Matthias Eberhard Glaser, Alan Cuthbertson
-
Patent number: 10087141Abstract: [18F]-fluoralkyl tosylates are useful building block for the radiosynthesis of a number of small molecules. A method of purifying [18F]-fluoroalkyl tosylates using an automated radiosynthesis apparatus (e.g. FASTlab module) is described. A method of purifying [18F]-fluoroalky tosylates using a FASTlab module that includes a solid phase extraction (SPE) purification system is described.Type: GrantFiled: August 21, 2014Date of Patent: October 2, 2018Assignee: GE HEALTHCARE LIMITEDInventors: Matthias Eberhard Glaser, Sajinder Luthra, Jane Brown, Robert James Nairne
-
Publication number: 20170106104Abstract: The present invention relates to the field of radiopharmaceuticals for in vivo imaging, in particular to automated methods for the preparation and purification of 18F-labelled tau imaging radiotracers. Also provided are interchangeable cassettes useful in the methods, and the use of automated synthesizers and cassettes in the methods.Type: ApplicationFiled: December 16, 2014Publication date: April 20, 2017Inventors: Duncan George Wynn, Steven Michael Fairway, Matthias Eberhard Glaser, Ian NEWINGTON, Gareth Edwin Smith, IMTIAZ Ahmed KHAN, Julian Grigg
-
Publication number: 20160176807Abstract: [18F]-fluoralkyl tosylates are useful building block for the radiosynthesis of a number of small molecules. A method of purifying [18F]-fluoroalkyl tosylates using an automated radiosynthesis apparatus (e.g. FASTlab module) is described. A method of purifying [18F]-fluoroalky tosylates using a FASTlab module that includes a solid phase extraction (SPE) purification system is described.Type: ApplicationFiled: August 21, 2014Publication date: June 23, 2016Inventors: Matthias Eberhard Glaser, Sajinder LUTHRA, Jane Brown, James Nairne
-
Patent number: 9061080Abstract: Imaging agents comprising an isolated polypeptide conjugated with a radionucleide and a chelator; wherein the isolated polypeptide binds specifically to HER2, or a variant thereof; and methods for preparing and using these imaging agents.Type: GrantFiled: December 19, 2011Date of Patent: June 23, 2015Assignee: GE HEALTHCARE LIMITEDInventors: Duncan Hiscock, Bard Indrevoll, Peter Iveson, Matthias Eberhard Glaser, Rajiv Bhalla, Anthony Wilson
-
Patent number: 8961930Abstract: Isatin 5-sulfonamide derivatives, pharmaceutical compositions comprising the derivatives, their use as molecular imaging agents, their use for the diagnosis or treatment of diseases or disorders associated with dysregulation of apoptosis, methods for synthesizing the derivatives, methods for the molecular imaging of caspase activity and apoptosis, and methods of assessing the therapeutic effect of a test substance on caspase activity are disclosed.Type: GrantFiled: September 4, 2009Date of Patent: February 24, 2015Assignees: Imperial Innovations Limited, Hammersmith Imanet LimitedInventors: Eric Ofori Aboagye, Graham Smith, Quang-De Nguyen, Erik Arstad, Matthias Eberhard Glaser
-
Publication number: 20150004100Abstract: Pyridazinone compounds of Formula I: (I) wherein: R? is alkyl or Ar, optionally substituted with at least one alkyl, halogen, hydroxyl, alkoxy, haloalkoxy, acid, ester, amino, nitro, amide, or alkoxyhalo; 2 R is independently alkyi, alkynyl, ester, amino, amide, acid, aryl, heteroaryl, aminoalkyl, —C(=0)alkyl, —C(=0)aryl, —C(=0)heteroaryl, —C(=0)heterocycloalkyl, —C(=0)heterocycloalkylAr, —C(=0)(CH2)nhalo, —C(?O)(CH2)nheterocyclyl, or —SC?Ar, optionally substituted with at least one alkyi, alkylhalo, halogen, nitro, aryl, heteroaryl, or heteroaryl(CH2)nhalo; R3 and R4 are independently hydrogen, alkyi, alkenyl, alkynyl, aryl, heteroaryl; Ar is an aryl, heteroaryl, cycloalkyl, heterocycloalkyl group; n is an integer from 0-10; or a radiolabeled derivative thereof. The compounds are useful as imaging probes of Tau pathology in Alzheimer's disease are described. Compositions and methods of making such compounds are also described.Type: ApplicationFiled: December 13, 2012Publication date: January 1, 2015Applicant: GE HEALTHCARE LIMITEDInventors: Clare Jones, Matthias Eberhard Glaser, Duncan Wynn, James Nairne, Umamaheshwar P. Mokkapati, Ian Martin Newington, Chitralekha Rangswamy, Jinto Jose, Saga Johansson
-
Patent number: 8795631Abstract: The present invention relates to 18F radio-chemistry and in particular to a method for synthesising radiofluorinated amides and amines. The method of the invention has particular application in the radiosynthesis of a variety of 18F-labelled positron emission tomography (PET) tracers.Type: GrantFiled: October 20, 2009Date of Patent: August 5, 2014Assignees: HammerSmith Imanet Limited, GE Healthcare LimitedInventors: Robert James Domett Nairne, Erik Arstad, Matthias Eberhard Glaser
-
Publication number: 20140127130Abstract: The present invention provides a process for [18F]-fluorination of biomolecules containing a primary amino group such as proteins and peptides and in particular of peptides. The invention further provides reagents for this process, in particular 18F-labelled prosthetic groups for use in the preparation as well as non-labelled intermediates useful in the preparation of the [18F]-labelled prosthetic groups. [18F]-labelled compounds useful as radiopharmaceuticals, specifically for use in Positron Emission Tomography (PET) are also provided.Type: ApplicationFiled: January 9, 2014Publication date: May 8, 2014Applicant: HAMMERSMITH IMANET LIMITEDInventors: ERIK ARSTAD, MATTHIAS EBERHARD GLASER
-
Patent number: 8679455Abstract: The invention relates to radiodiagnostic and radiotherapeutic agents, including biologically active vectors labelled with radionuclides. It further relates to methods of making such radiodiagnostic and radiotherapeutic agents and the compounds used in such methods. The resultant labelled conjugates are useful as diagnostic agents, for example, as radiopharmaceuticals more specifically for use in Positron Emission Tomography (PET) or Single Photon Emission Computed Tomography (SPECT) or for radiotherapy.Type: GrantFiled: June 13, 2011Date of Patent: March 25, 2014Assignee: Hammersmith Imanet LimitedInventors: Erik Arstad, Matthias Eberhard Glaser
-
Patent number: 8629299Abstract: The present invention provides a process for [18F]-fluorination of biomolecules containing a primary amino group such as proteins and peptides and in particular of peptides. The invention further provides reagents for this process, in particular 18F-labelled prosthetic groups for use in the preparation as well as non-labelled intermediates useful in the preparation of the [18F]-labelled prosthetic groups. [18F]-labelled compounds useful as radiopharmaceuticals, specifically for use in Positron Emission Tomography (PET) are also provided.Type: GrantFiled: May 20, 2013Date of Patent: January 14, 2014Assignee: Hammersmith Imanet LimitedInventors: Erik Arstad, Matthias Eberhard Glaser
-
Publication number: 20130343990Abstract: Novel radiotracer(s) for Positron Emission Tomography (PET) imaging are described. Novel radiotracer(s) for Positron Emission Tomography (PET) imaging of neuorendocrine tumors are described. Specifically the present invention describes novel [18F]Fluoroethyltriazol-[Tyr3]Octreotate analogs; in particular those that target somatostatin receptors found on the cell surface of gastroenteropancreatic neuorendocrine tumors. The present invention also describes intermediate(s), precursor(s), pharmaceutical composition(s), methods of making, and methods of use of the novel radiotracer(s).Type: ApplicationFiled: March 1, 2012Publication date: December 26, 2013Applicants: IMPERIAL COLLEGE, GE HEALTHCARE LIMITEDInventors: Sajinker Kaur Luthra, Julius Leyton, Eric Ofori Aboagye, Lisa Iddon, Bard Indrevoll, Matthias Eberhard Glaser, Alan Cuthbertson
-
Publication number: 20130295010Abstract: Imaging agents comprising an isolated polypeptide conjugated with a radionucleide and a chelator; wherein the isolated polypeptide binds specifically to HER2, or a variant thereof; and methods for preparing and using these imaging agents.Type: ApplicationFiled: December 19, 2011Publication date: November 7, 2013Inventors: Duncan Hiscock, Bard Indrevoll, Peter Iveson, Matthias Eberhard Glaser, Rajiv Bhalla, Anthony Wilson
-
Publication number: 20130287685Abstract: Imaging agents comprising an isolated polypeptide conjugated with a radionucleide and a chelator; wherein the isolated polypeptide binds specifically to HER2, or a variant thereof; and methods for preparing and using these imaging agents.Type: ApplicationFiled: December 19, 2011Publication date: October 31, 2013Applicant: GE HEALTHCARE LIMITEDInventors: Duncan Hiscock, Brad Indrevoll, Peter Iveson, Matthias Eberhard Glaser, Rajiv Bhalla, Anthony Wilson
-
Publication number: 20130259802Abstract: The present invention provides a process for [18F]-fluorination of biomolecules containing a primary amino group such as proteins and peptides and in particular of peptides. The invention further provides reagents for this process, in particular 18F-labelled prosthetic groups for use in the preparation as well as non-labelled intermediates useful in the preparation of the [18F]-labelled prosthetic groups. [18F]-labelled compounds useful as radiopharmaceuticals, specifically for use in Positron Emission Tomography (PET) are also provided.Type: ApplicationFiled: May 20, 2013Publication date: October 3, 2013Applicant: HAMMERSMITH IMANET LIMITEDInventors: ERIK ARSTAD, MATTHIAS EBERHARD GLASER
-
Publication number: 20130189186Abstract: The present invention relates to radiopharmaceutical imaging in vivo of apoptosis. The invention provides imaging agents which target apoptotic cells via selective binding to the aminophospholipid phosphatidylethanolamine (PE), which is exposed on the surface of apoptotic cells. The radiopharmaceuticals comprise radiometal complexes of chelator conjugates of PE-binding peptides. Also provided are pharmaceutical compositions, kits and methods of in vivo imaging.Type: ApplicationFiled: September 27, 2011Publication date: July 25, 2013Applicant: GE HEALTHCARE LIMITEDInventors: Bard Indrevoll, Duncan Hiscock, Bente Elizabeth Arbo, Rajiv Bhalla, Matthias Eberhard Glaser, Graeme Walter McRobbie
-
Patent number: 8445721Abstract: The present invention provides a process for [18F]-fluorination of biomolecules containing a primary amino group such as proteins and peptides and in particular of peptides. The invention further provides reagents for this process, in particular 18F-labelled prosthetic groups for use in the preparation as well as non-labelled intermediates useful in the preparation of the [18F]-labelled prosthetic groups. [18F]-labelled compounds useful as radiopharmaceuticals, specifically for use in Positron Emission Tomography (PET) are also provided.Type: GrantFiled: March 8, 2012Date of Patent: May 21, 2013Assignee: Hammersmith Imanet LimitedInventors: Erik Arstad, Matthias Eberhard Glaser
-
Patent number: 8409547Abstract: The invention relates to radiodiagnostic and radiotherapeutic agents, including biologically active vectors labelled with radionuclides. It further relates to methods and reagents labelling a vector such as a peptide comprising reaction of a compound of formula (I) with a compound of formula (II): R*-L2-C?N+—O???(II) or, a compound of formula (III) with a compound of formula (IV) in the presence of a Cu (I) catalyst. The resultant labelled conjugates are useful as diagnostic agents, for example, as radiopharmaceuticals more specifically for use in Positron Emission Tomography (PET) or Single Photon Emission Computed Tomography (SPECT) or for radiotherapy.Type: GrantFiled: June 25, 2012Date of Patent: April 2, 2013Assignee: Hammersmith Imanet LimitedInventors: Matthias Eberhard Glaser, Erik Arstad
-
Publication number: 20120282171Abstract: The invention relates to radiodiagnostic and radiotherapeutic agents, including biologically active vectors labelled with radionuclides. It further relates to methods and reagents labelling a vector such as a peptide comprising reaction of a compound of formula (I) with a compound of formula (II): R*-L2-C?N+—O???(II) or, a compound of formula (III) with a compound of formula (IV) in the presence of a Cu (I) catalyst. The resultant labelled conjugates are useful as diagnostic agents, for example, as radiopharmaceuticals more specifically for use in Positron Emission Tomography (PET) or Single Photon Emission Computed Tomography (SPECT) or for radiotherapy.Type: ApplicationFiled: June 25, 2012Publication date: November 8, 2012Applicant: HAMMERSMITH IMANET LIMITEDInventors: MATTHIAS EBERHARD GLASER, ERIK ARSTAD